Early aortic valve replacement for asymptomatic severe aortic stenosis: an updated systematic review and meta-analysis
In brief
Early valve replacement lowers hospitalizations and stroke, but not mortality
In randomized trials of people with asymptomatic severe aortic stenosis, early surgical or transcatheter valve replacement reduced cardiovascular and heart failure hospitalizations and stroke compared with surveillance. It did not significantly reduce deaths overall or from cardiovascular causes, and benefits appeared to vary with valve severity and comorbidity, supporting individualized decisions rather than routine early intervention for everyone.
- Journal
- Progress in cardiovascular diseases (Q1)
- Published
- 29 September 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Francesco Cannata, Alberico Del Torto, Kamil Stankowski, Fabio Fazzari, Valentina Mantegazza, Luigi Tassetti, et al.
- PMID
- 42810703
- DOI
- 10.1016/j.pcad.2026.09.005
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (top studies of the week, 4 October 2026): Early AVR for asymptomatic severe AS meta‑analysis
- Picked for Internal Medicine (top studies of the week, 4 October 2026): Ranked by evidence level and journal quartile
Abstract
BACKGROUND: The optimal timing of intervention in asymptomatic severe aortic stenosis remains debated. This updated meta-analysis evaluates the comparative effects of early surgical or transcatheter aortic valve replacement (AVR) versus conservative management by incorporating recent long-term randomized evidence. METHODS: We performed a systematic review and meta-analysis of randomized trials comparing early AVR with conservative management in asymptomatic severe AS. Hazard ratios and 95% confidence intervals were pooled using a random-effects model, and exploratory meta-regression analyses were conducted to identify potential treatment-effect modifiers. RESULTS: Across the included randomized trials, an early intervention strategy was associated with significant reductions in cardiovascular hospitalizations, heart failure hospitalizations, and stroke. Reductions in all-cause and cardiovascular mortality favored early intervention but did not achieve statistical significance. Treatment benefits varied according to clinical and hemodynamic profiles: greater baseline valve severity was associated with larger therapeutic effects, whereas increasing comorbidity burden (such as diabetes) tended to result in inferior clinical outcomes. CONCLUSIONS: In asymptomatic severe AS, an early AVR strategy consistently reduces cardiovascular and heart failure hospitalizations and stroke compared with conservative surveillance, despite neutral effects on overall and cardiovascular mortality. These findings support a contemporary shift toward an individualized, phenotype-driven approach rather than universal early intervention. Integrating hemodynamic severity and comorbidity burden can help identify patients most likely to derive net clinical benefit from early valve replacement.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.